Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Genedrive extends global coverage with new distribution agreement in India

The AIM-listed diagnostics manufacturer said the agreement will focus on securing regulatory approvals for its HCV ID Kit in India
Scientist using microscope
Genedrive said it would retain responsibility for product development, quality management and manufacturing

Genedrive PLC (LON:GDR) has signed a new distribution agreement for its Genedrive HCV ID Kit and Genedrive platform in India.

The AIM-listed diagnostics manufacturer said the agreement made with ARKRAY Healthcare pvt Ltd (ARKRAY), a subsidiary of ARKRAY Inc. Japan, will focus on securing regulatory approvals for the HCV ID Kit in India.

READ: Genedrive continues to execute on its strategy to focus fully on molecular diagnostics

Genedrive added that it would retain responsibility for product development, quality management and manufacturing, with commercial activities expected to begin in the latter part of its 2018/19 financial year.

ARKRAY will be responsible for sales, marketing, customer support and distribution activities across the region, the group said.

The development is another step in the firms push into global commercial territory, having begun commercial sales and shipments of its HCV ID Kit into the EMEA region in mid-March.

David Budd, Genedrive chief executive, said: "We are extremely pleased to extend our commercial reach into India with ARKRAY, who have established an extensive and respected diagnostic sales and support business in the Indian market. This agreement provides access to another important and very relevant region for Genedrive through a world class commercial partner."

View full GDR profile View Profile

Genedrive PLC Timeline

CN Video
January 22 2018

Related Articles

test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
1524140870_ampoules.jpg
April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use